中国P站

Antimicrobial Resistance; Pediatric Infectious Diseases; Vaccine-Preventable Diseases; Diagnostics; COVID-19; Severe Acute Malnutrition (SAM); Neonatal Sepsis; Immunomodulation; Drug-Resistant Tuberculosis (DR-TB); Neglected Tropical Diseases (NTDs); Emerging Viral Pathogens; Zoonotic Infections; Child Health; Public Health

Introduction

Antimicrobial resistance (AMR) in pediatric infectious diseases is a significant global health challenge, driven by factors like irrational antibiotic use and limited novel drug development. Addressing this requires a multifaceted approach, emphasizing improved surveillance, rational prescribing practices, infection prevention, and international collaboration. Future efforts must focus on developing new antibiotics and vaccines tailored for children, alongside implementing stewardship programs to safeguard treatment options for future generations [1].

An analysis of European surveillance data from 2017 to 2021 reveals that vaccine-preventable diseases continue to pose a substantial public health burden in Europe, with significant numbers of reported cases, hospitalizations, and deaths across various age groups, including children. While vaccine uptake remains generally high, persistent gaps and regional disparities highlight the ongoing need for robust immunization programs, continuous surveillance, and targeted interventions to improve vaccine confidence and achieve optimal coverage [2].

The landscape of diagnostics for pediatric infectious diseases is rapidly evolving, with a growing array of molecular, proteomic, and immunological tools offering improved sensitivity and specificity for pathogen detection. These advancements are crucial for timely diagnosis, guiding appropriate treatment, and minimizing antibiotic overuse in children. However, challenges remain in widespread implementation, cost-effectiveness, and ensuring equitable access, particularly for emerging pathogens and in resource-limited settings [3].

A retrospective cohort study from Ethiopia investigated COVID-19 characteristics in children with severe acute malnutrition (SAM), finding that SAM significantly exacerbates disease severity and increases adverse outcomes. Children with both SAM and COVID-19 experienced higher rates of complications and mortality compared to those without SAM, underscoring the critical need for integrated health interventions that address both malnutrition and infectious disease management in vulnerable pediatric populations [4].

Neonatal sepsis remains a leading cause of morbidity and mortality in newborns globally, presenting significant diagnostic challenges due to non-specific clinical signs and limitations of current diagnostic tools. Recent advances include the exploration of novel biomarkers, molecular assays, and rapid point-of-care tests. Overcoming these diagnostic hurdles is crucial for earlier detection, targeted antimicrobial therapy, and ultimately, improved outcomes for affected infants [5].

Immunomodulation plays a critical role in the pathogenesis and treatment of pediatric infectious diseases, influencing both host defense and disease severity. Understanding the complex interplay between pathogens and the developing immune system opens avenues for novel therapeutic strategies beyond conventional antimicrobials. Tailored immunomodulatory approaches could potentially mitigate excessive inflammation, enhance immune responses, and improve outcomes in children with severe infections, reducing reliance on broad-spectrum antibiotics [6].

Drug-resistant Tuberculosis (DR-TB) in children is a growing global health concern, presenting significant challenges in epidemiology, diagnosis, and management due to the complexity of pediatric disease presentation and limited availability of child-friendly drug formulations. A comprehensive scoping review highlights the urgent need for improved surveillance, rapid and accurate diagnostic tools adapted for children, and optimized treatment regimens to curb the spread of DR-TB and reduce its burden in this vulnerable population [7].

Neglected Tropical Diseases (NTDs) impose a substantial and often underestimated burden on children globally, particularly in poverty-stricken regions, leading to chronic illness, developmental delays, and impaired educational attainment. This analysis underscores the critical need for integrated control programs that combine preventive chemotherapy, improved sanitation, health education, and case management tailored for pediatric populations to alleviate the long-term impact of NTDs on child health and development [8].

The pediatric population is uniquely vulnerable to emerging and re-emerging viral pathogens due to their developing immune systems and often increased exposure risks. This review highlights the ongoing threat posed by viruses like SARS-CoV-2, dengue, and novel influenza strains, emphasizing the importance of continuous surveillance, rapid diagnostic development, and vaccine research tailored for children. Proactive public health strategies are essential to mitigate the impact of these evolving viral threats on child health worldwide [9].

Zoonotic infections pose a significant and often underestimated global threat to child health, driven by close human-animal interactions and environmental factors. This review synthesizes current knowledge on the epidemiology, diverse clinical manifestations, and crucial prevention strategies for various zoonoses impacting pediatric populations. Effective control requires a 'One Health' approach, integrating human, animal, and environmental health sectors to minimize transmission risk and protect children from these pervasive diseases [10].

Description

Pediatric infectious diseases represent a multifaceted global health challenge, encompassing a range of threats from bacterial resistance to emerging viral pathogens. One major area of concern is Antimicrobial Resistance (AMR) in children, a problem driven by factors like inappropriate antibiotic use and a lack of new drug development. Effective solutions require a broad strategy, including better surveillance, careful prescribing, robust infection prevention, and strong international cooperation. Future efforts are critical to develop new antibiotics and vaccines specifically for children and to implement stewardship programs to preserve existing treatments for coming generations [1].

Vaccine-preventable diseases continue to be a significant public health issue, especially across Europe, as shown by surveillance data from 2017-2021. Despite generally high vaccine uptake, gaps and regional differences persist, emphasizing the ongoing need for strong immunization efforts, constant monitoring, and targeted interventions to boost vaccine confidence and achieve optimal coverage [2]. Alongside this, diagnostic methods for pediatric infectious diseases are rapidly advancing. Molecular, proteomic, and immunological tools now offer improved sensitivity and specificity, enabling faster and more accurate pathogen detection. These innovations are key for timely diagnoses, guiding appropriate treatment, and reducing unnecessary antibiotic use in children. Still, challenges remain regarding their widespread adoption, cost-effectiveness, and fair access, particularly for new pathogens and in areas with limited resources [3].

Vulnerable populations within pediatrics face unique risks. For example, a study from Ethiopia revealed that children with severe acute malnutrition (SAM) who contracted COVID-19 experienced more severe disease and worse outcomes. This finding highlights the urgent need for integrated health interventions that tackle both malnutrition and infectious disease management in these susceptible young populations [4]. Similarly, neonatal sepsis remains a leading cause of illness and death in newborns worldwide. Diagnosing it is often difficult due to non-specific clinical signs and the limitations of current diagnostic tests. However, new developments, such as the exploration of novel biomarkers, molecular assays, and rapid point-of-care tests, offer promising avenues for earlier detection, targeted antimicrobial therapy, and ultimately, better results for affected infants [5].

Beyond conventional treatments, immunomodulation is emerging as a critical factor in the progression and management of pediatric infectious diseases. Understanding how pathogens interact with a child's developing immune system can lead to new therapeutic strategies that go beyond traditional antimicrobials. Customized immunomodulatory approaches could help reduce excessive inflammation, strengthen immune responses, and improve outcomes for children with severe infections, lessening the need for broad-spectrum antibiotics [6]. Another significant threat is drug-resistant Tuberculosis (DR-TB) in children. This is a growing global health concern with complex epidemiological, diagnostic, and management challenges, partly due to how the disease presents in children and the limited availability of child-friendly drug forms. A comprehensive review points to an urgent need for better surveillance, quick and accurate diagnostic tools designed for children, and optimized treatment plans to control the spread of DR-TB and ease its burden on this vulnerable group [7].

Furthermore, neglected tropical diseases (NTDs) place a substantial, often overlooked, burden on children globally, particularly in impoverished areas. These diseases lead to chronic illness, developmental delays, and reduced educational achievement. This situation demands integrated control programs that combine preventive chemotherapy, improved sanitation, health education, and case management specifically designed for pediatric populations. Such initiatives are vital to lessen the long-term impact of NTDs on child health and development [8]. Lastly, children are especially susceptible to emerging and re-emerging viral pathogens due to their developing immune systems and often higher exposure risks. Viruses like SARS-CoV-2, dengue, and new influenza strains pose ongoing threats, underscoring the importance of continuous surveillance, rapid diagnostic innovation, and vaccine research tailored for children. Proactive public health strategies are indispensable to lessen the global impact of these evolving viral threats on child health [9]. Zoonotic infections, transmitted between animals and humans, also present a significant and often underestimated global risk to child health. These are influenced by close human-animal interactions and environmental factors. A "One Health" approach, integrating human, animal, and environmental health sectors, is necessary to minimize transmission risks and protect children from these widespread diseases [10].

Conclusion

Pediatric infectious diseases present complex global health challenges, touching on Antimicrobial Resistance (AMR), vaccine-preventable diseases, diagnostic advancements, and specific severe conditions. Antimicrobial Resistance (AMR) in children is a major concern, requiring better surveillance and rational antibiotic use to preserve future treatment options. Concurrently, vaccine-preventable diseases continue to burden Europe, making strong immunization programs and continuous surveillance essential. Progress in molecular, proteomic, and immunological diagnostics offers hope for earlier detection and appropriate treatment, although widespread implementation faces hurdles. Specific vulnerabilities exist, like children with severe acute malnutrition (SAM) and COVID-19, who face worse outcomes, highlighting the need for integrated health interventions. Neonatal sepsis remains a significant cause of mortality, driving the search for new biomarkers and rapid diagnostic tests. Immunomodulation is gaining recognition for its role in altering disease severity and potentially reducing reliance on broad-spectrum antibiotics. Drug-resistant Tuberculosis (DR-TB) in children demands improved diagnostics and child-friendly treatments. Neglected Tropical Diseases (NTDs) also significantly impact child development, necessitating integrated control programs. Furthermore, the pediatric population is uniquely susceptible to emerging viral pathogens, underscoring the need for ongoing surveillance and vaccine research. Finally, zoonotic infections pose an underestimated threat, emphasizing a "One Health" approach for prevention. These diverse challenges point to a unified goal: protecting children's health through comprehensive, collaborative, and innovative strategies.

References

1. Ziya A, Elif Ç, Özlem G (2024) .Infect Disord Drug Targets 24:11-23.

   , ,

2. Gianfranco S, Maja P, Mircea IP (2023) .Vaccines (Basel) 11:1787.

   , Google Scholar,

3. Sarah KP, Emily KS, Anna PH (2023) .J Infect Dis 228:S121-S135.

   , ,

4. Kidist Y, Mulugeta B, Tigist W (2024) .PLoS One 19:e0296716.

   , ,

5. Mariya TK, Oksana PP, Viktor MS (2024) .Pediatr Neonatol 65:1-9.

   , ,

6. Anna S, Elena K, Polina S (2023) .Int J Mol Sci 24:16168.

   , ,

7. Nazia S, Suthashini G, Kaviarasan M (2023) .Int J Environ Res Public Health 21:40.

   , ,

8. Ayodeji MO, Olalekan AA, Oluwafemi OA (2023) .J Trop Pediatr 69:fmad051.

   , ,

9. Pooja R, Megha S, Shweta M (2023) .J Pure Appl Microbiol 17:1877-1887.

   , ,

10. Zeynep Ö, Elif Ç, Ay艧e K (2024) .J Environ Public Health 2024:9942699.

    , ,